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EXPRESSION OF MUC2 GLYCOPROTEIN ANTIBODY  
AND VASCULAR ENDOTHELIAL GROWTH FACTOR  
IN BARRETT’S MUCOSA
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SUMMARY – Higher expression of the mucin 2 (MUC2) glycoprotein and vascular endothelial 
growth factor (VEGF) in Barrett’s mucosa may be associated with a higher risk of esophageal adeno-
carcinoma development. Thirty-six patients diagnosed with Barrett’s esophagus (BE), short-segment, 
were included in the study due to unsuccessful treatment with proton pump inhibitors. The diagnosis 
was confirmed by histopathologic analysis of the tissue obtained by esophagogastric junction biopsy. 
Expression of MUC2 and VEGF was determined by immunohistochemistry. We found four patients 
in early stage of adenocarcinoma and 32 patients with BE; five of them had indication for argon 
plasma coagulation treatment, one for radiofrequency ablation and one for endoscopic mucosal resec-
tion; 25 patients were treated with proton pump inhibitors. Regression of BE occurred in 25 (69.44%) 
patients. MUC2 positivity is unique for goblet cells in patients with BE, but it is not the only marker. 
VEGF is an indicator of angiogenesis in the mucosa of patients with BE and adenocarcinoma.
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Introduction
The nature of Barrett’s esophagus (BE) (Fig. 1), 
progression and rate of progression to malignant dis-
ease has not yet been fully explored, and for now, there 
are no biochemical-immunohistochemical-histopath-
ologic markers that are highly specific for the diagno-
sis of this disease1,2. BE was twenty times less fre-
quently diagnosed in patients than on autopsy1-3. Evo-
lution of BE to cancer takes 20 to 30 years1,3. A study 
by Garud et al.4 demonstrated the prevalence of BE to 
range from 0.9% to 4.5%, with progression to adeno-
carcinoma (AC) in 0.5% per patient per year. Helico-
bacter pylori (H. pylori) positive patients have milder 
forms of gastroesophageal reflux disease (GERD), BE 
and lower esophageal stricture compared to those that 
are H. pylori negative5. Over the past 20 years, the inci-
dence of esophageal and esophagogastric junction AC 
was higher than the incidence of any other cancer in 
the human population3.
Mucin 2 (MUC2), a mucin family glycoprotein, 
has been located in the cytoplasm of goblet cells in-
cluding small intestine, colon, bronchus, salivary gland, 
conjunctiva of the eye, but not in normal gastric mu-
cosa. In the context of the study of malignant diseases, 
MUC2 positive finding was recorded in primary gas-
trointestinal tumors of the colon, stomach and esopha-
gus; goblet cells in the tissue of metastatic colorectal 
cancer in the ovary, but not in primary ovarian muci-
nous AC; and intestinal metaplasia of the esophagus 
(BE), where expression of MUC2 is shown in goblet 
cells6-10. Accordingly, the questions are: is MUC2 anti-
body a predictive marker for BE regression in patients 
treated with proton pump inhibitors (PPIs), argon 
plasma coagulation (APC) and/or combination thera-
py; is its presence associated with progression to dys-
plasia; and is there expression of the same gene in pa-
tients with AC of the esophagus?
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Vascular endothelial growth factor (VEGF) is a 
signaling protein involved in the process of vasculo-
genesis and angiogenesis. When a cell lacks oxygen, it 
produces hypoxia inducible factor (HIF), which stim-
ulates the release of VEGF and its binding to the re-
ceptor tyrosine kinase, as a precondition for angiogen-
esis11-14. Expression of VEGF was shown to be an im-
portant factor in creating a vascular network of tumor 
growth and metastasis in various and numerous tu-
mors that occur in the human population, such as 
breast, liver, colon, gastric AC and squamous cell carci-
noma of the esophagus14. Endocrine cells with meta-
plastic altered mucosa showed expression of VEGF in 
the cytoplasm11.
The aim of this study was to examine the expres-
sion of MUC2 and VEGF in patients with proven BE.
Patients and Methods
Study group
Thirty-six patients with BE treated with PPIs were 
included in the study. Patients were collected during a 
period of more than 6 years. In addition to standard 
procedure (history, physical examination, abdominal 
ultrasound, basic laboratory findings), esophagogas-
troduodenoscopy (EGDS) with biopsy of esophago-
gastric junction was performed in all patients. During 
a follow up period of 3-6 years, they underwent regular 
annual endoscopy with biopsies.
This clinical trial enrolled 36 patients aged 18-80 
years with GERD and proven existence of BE or AC. 
All patients were treated at Department of Gastroen-
terology, Zadar General Hospital from Zadar, Croatia. 
Control group consisted of the same subjects treated 
after proven BE diagnosis that underwent repeat pro-
tocol examinations following appropriate therapy ac-
cording to the guidelines. Inclusion criteria: subjects of 
both sexes aged 18-80 years with no previously known 
malignancy; respondents with positive reflux symp-
toms; respondents not using anticoagulant therapy; 
and existence of esophagogastric junction changes in 
terms of BE or AC. Exclusion criteria: patients aged 
<18 or >80 years; history of malignant disease; patients 
already treated with a PPI for GERD and without 
previously made EGDS; subjects on anticoagulant 
therapy; and subjects that did not understand the 
questionnaire.
Methods
The study involved subjects in which the histo-
pathologic analysis verified the existence of BE (Fig. 
2) or AC, and the same subjects after BE treatment 
with PPI and/or APC, radiofrequency ablation (RFA), 
endoscopic mucosal resection (EMR), or after esopha-
gectomy. Patients filled out a questionnaire about 
GERD. Histopathologic analysis included immuno-
histochemistry of MUC2 and VEGF. Multisystem-
immunohistochemical analysis was performed at the 
Department of Pathology and Forensic Medicine, Za-
Fig. 1. Endoscopic view of affected esophagogastric 
mucosa. Fig. 2. The S area shows how the squamous cells that line 
the esophagus appear under the microscope, whereas B 
area shows Barrett’s metaplasia; the arrow points to 
goblet cells characteristic of Barrett’s metaplasia.
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dar General Hospital, on a DAKO Whale device 
(DAKO, Santa Clara, USA) with antibodies from the 
same manufacturer, as follows: first kit EnVision 
FLEX HIGH pH, MO A-Hu MUC2, clone CCP58 
and VEGF Clone: VG1, Isotype: IgG1 kappa; second 
kitMO-HU Vascular Endothelial Growth Factor.
All patients signed an informed consent and the 
study was conducted in accordance with ethical prin-
ciples of the Helsinki Declaration.
Immunohistochemistry of MUC 2 and VEGF
At the Laboratory of Immunohistochemistry, De-
partment of Pathology, Cytology and Forensic Medi-
cine, Zadar General Hospital, 3-4 μm thick prepara-
tions were cut from paraffin blocks of the tumor tissue 
and then mounted on silanized slides. After cutting, 
they were heated in a thermostat at 60 °C for one hour 
and then stained by applying indirect immunochemis-
try without biotin using ULTRAVIEW Universal 
DAB Detection Kit, Ventana brand. Further proce-
dures required for immunohistochemical analysis were 
performed on a fully automated Ventana Benchmark-
GX platform. The MUC2 colon tissue was used as 
positive control. Findings were interpreted as follows: 
0, no cell staining; 1, at least 30% of staining cells; 2, 
31%-60% of staining cells; and 3, >60% of staining 
cells.
Tonsil tissue was used as positive control for VEGF. 
Findings were interpreted as follows: samples stained 
with anti-VEGF-antibody like yellow-brown granules 
in the cytoplasm of the cells or plasma membrane. 
Negative sample had 0-30% of cells with VEGF, and 
positive sample had 31%-100% of staining cells.
Statistical analysis
The results were described as parameters of de-
scriptive statistics using one-way analysis of variance 
(ANOVA), Mann-Whitney test and χ2-test. The level 
of significance was set at p<0.05. Data were processed 
using the Statistica 13.0 software.
Results
We identified four patients in early stage of AC 
and 32 patients with BE (Table 1); five of them had 
indication for APC treatment (including criteria for 
APC such as intestinal metaplasia or no dysplasia or 
low-grade dysplasia), and one for RFA and EMR each. 
Twenty-five patients were treated with PPIs. Regres-
sion of BE occurred in 25 (69.44%) patients. We noted 
an interesting phenomenon that higher expression of 
MUC2 was inversely proportionate to VEGF in seven 
patients (all with carcinoma and three with BE). After 
all treatment modalities, patients reported reduction or 
complete disappearance of regurgitation, burning sen-
sation and dyspepsia. Our patients mostly had low-
risk BE, and two patients with high-risk BE had posi-
tive findings of MUC2, VEGF, dysplasia and metapla-
sia; they were treated with more aggressive treatment 
methods such as RFA and EMR.
In patients with only mucosal changes in terms of 
intestinal metaplasia, after APC treatment we found 
regression of these changes, and endoscopic findings 
and biopsy confirmed only GERD or healthy oral mu-
cosa. In patients with mucosal changes in terms of in-
testinal metaplasia and dysplasia of mild to moderate 
degree, there was no significant regression of symp-
toms, and regression was of short duration (maximum 
one year).
In the period between first and second examina-
tion, significant changes were recorded in VEGF 
(χ2=4.65, df=1; p=0.031). Therapy administered be-
tween the first and second examination significantly 
influenced VEGF reduction in BE patients (precisely, 
reduced it to 0), but there was no significant effect on 
MUC2 reduction.
Immunohistochemistry results coincided with sta-
tistics, i.e. there was no causative relationship of posi-
tive MUC2 and VEGF findings with a higher degree 
of dysplasia and/or metaplasia, nor they were associ-
ated with a higher incidence of H. pylori positive find-
ings, but clearly indicated the existence of intestinal 
metaplasia and/or dysplasia.
Table 1. Distribution of patients according to diagnosis
Clinical diagnosis 1
st examination 2nd examination
n (%) n (%)
GERD 0 25 (69.445%)
Barrett’s esophagus 32 (88.89%) 7 (19.445%)
Carcinoma 4 (11.11%) 0
Operated 0 4 (11.11%)
Total 36 (100%) 36 (100%)
GERD = gastroesophageal reflux disease
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Fisher exact test was significant (p=0.017), which 
means that patients with AC and those with BE could 
be distinguished based on the H. pylori expression on 
esophageal mucosa, i.e. H. pylori expression would be 
lower in AC patients. As already mentioned, this find-
ing should be interpreted with caution because we had 
only four patients with AC.
Discussion
Expression of MUC2 is characteristic of goblet 
cells, which also are a unique but not the only histo-
pathologic marker of BE. Unaffected mucosa has no 
goblet cells and is not positive for MUC215. Research 
has confirmed that the existence of VEGF is not spe-
cific to metaplasia of stratified squamous epithelium in 
the single cylinder, which is another characteristic his-
topathologic finding in BE. We found changes of mu-
cous membranes with intestinal metaplasia, dysplasia, 
and new vascular network in the tissue affected with 
neoplastic alterations.
Since all subjects were administered PPIs with ad-
ditional endoscopic interventions in those with histo-
logically aggressive disease, it is concluded that the 
mentioned therapy with PPIs had significant effect on 
the reduction of VEGF between the two examina-
tions, but had no significant effect on reducing MUC2, 
which was negative after ablative techniques such as 
RFA and EMR16.
Study results revealed that MUC2 could not dis-
tinguish subjects with AC and those with BE. The rea-
son is that goblet cells were found in both BE and 
AC17. Patients with AC and those with BE could not 
be distinguished by VEGF either. This could be ex-
plained by the fact that the presence of VEGF was 
found in both BE and AC18. Couvelard et al.18 demon-
strated that VEGF expression correlated with vascu-
larization, but had no independent prognostic value. 
Our sample of only four patients certainly was too 
small to make any definite conclusion on non signifi-
cance of MUC2 and VEGF expression. We need to 
examine a larger number of patients in future studies.
Immunohistochemical results coincided with sta-
tistics, i.e. positive MUC2 and VEGF findings were 
not causally related to a higher degree of dysplasia 
and/or intestinal metaplasia, and were not associated 
with greater incidence of H. pylori positive findings but 
clearly pointed to the existence of intestinal metaplasia 
and/or dysplasia. Intestinal metaplasia can develop 
wherever there is squamous epithelium, and transition 
to dysplasia is the last step in the development of can-
cer. In the study by Garud et al., the prevalence of BE 
ranged from 0.9% to 4.5%, with progression to AC in 
0.5% per patient per year4.
Expression of H. pylori differed significantly be-
tween AC and BE patients (p=0.017), which means 
that patients with BE could be distinguished from 
those with AC based on the expression of the bacteri-
um on esophageal mucosa, which was lower in the lat-
ter. This finding should be interpreted with caution 
because we had only four patients with AC. This thesis 
should also be confirmed in future works on a much 
larger number of patients. Similar results have been 
reported by Sharma et al., that the presence of H. py-
lori in gastric mucosa has a protective activity on the 
esophagogastric junction in BE19.
Mucin expression in progressive stages of chronic 
gastritis and gastric epithelial infection with H. pylori 
provides identification of intestinal metaplasia, which 
is characterized by reduced expression of gastric mu-
cins (MUC5AC and MUC6) and de novo expression 
of MUC220. MUC2 is a reliable indicator of intestinal 
metaplasia, which occurs in H. pylori infected patients 
with chronic gastritis20. Whether it means protection 
of gastric mucosa from AC, remains as an idea to be 
tackled in future work. Therefore, the statistical result 
according to which AC patients have lower H. pylori 
expression must be taken as an indication that we need 
to check in future research.
In conclusion, MUC2 positivity is unique in goblet 
cells in patients with BE, but it is not the only marker. 
VEGF is an indicator of angiogenesis in the mucosa of 
patients with BE with or without intestinal metaplasia 
and dysplasia, and in patients with AC. The study of 
MUC2 and VEGF in cells with a high degree of dys-
plasia and AC of the esophagus in the general popula-
tion remains a subject for future research. A specific 
biomarker for detection of BE is yet to be discovered.
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Sažetak
IZRAŽENOST GLIKOPROTEINSKOG ANTITIJELA MUC2  
I VASKULARNOG ENDOTELNOG ČIMBENIKA RASTA (VEGF)  
U SLUZNICI BARRETTOVA JEDNJAKA
M. Ražov Radas
Izražajnost glikoproteina mucina 2 (MUC2) i vaskularnog endotelnog faktora rasta (VEGF) u sluznici Barrettova jed-
njaka (BJ) može se dovesti u vezu s višim rizikom razvoja adenokarcinoma jednjaka. Studija je obuhvatila 36 bolesnika s 
 dijagnozom BJ koja je potvrđena patohistološkom analizom nakon višestrukih biopsija ezofagogastričnog spoja. Izražajnost 
MUC2 i VEGF-a je prikazana imunohistokemijskom analizom. Otkrivena su četiri bolesnika u ranom stadiju adenokarci-
noma (učinjena je totalna ezofagektomija) i 32 bolesnika s BJ, od kojih je petoro imalo indikaciju za argon plazma koagula-
ciju, jedan za endoskopsku resekciju sluznice, jedan za radiofrekventnu ablaciju, a 25 ih je liječeno inhibitorima protonske 
pumpe. Regresija BJ je zabilježena u 25 (69,44%) bolesnika. Pozitivan nalaz MUC2 je karakterističan za vrčaste stanice u BJ, 
ali nije jedini biljeg. VEGF je pokazatelj angiogeneze u sluznici boelsnika s BJ i adenokarcinomom.
Ključne riječi: Barrettov jednjak; Mucin 2; Vaskularni endotelni faktor rasta; Protonska pumpa, inhibitori; Vrčaste stanice
